Today, on
The board of directors
The EGM resolved that the board of directors should consist of seven board members. Before the resolution was made the board of directors consisted of six board members.
Resolution on issue authorisation
The EGM resolved to authorise the Board of Directors to, on one or more occasions before the next Annual General Meeting, resolve on new issue of shares, share warrants or convertibles. The Board of Directors undertook to only use the authorization as regards issues of shares. The authorisation resolved upon is limited to 5 percent of the total amount of outstanding shares in the company as per the date of the notice. A new issue adopted in virtue of the authorisation, shall take place at market conditions and shall be carried out with a view to fulfil the company's payment obligation towards
Resolutions concerning issue and transfer of warrants to senior executive and board members in
The EGM resolved, through two separate resolutions, on the issue and transfer of warrants to a senior executive in accordance with the proposal made by the board of directors and to two board members in accordance with the proposal made by Östersjöstiftelsen.
The two resolutions entail that the company issues at most 117,000 warrants, each entitling the holder to subscribe for one new share in the company. The warrants are issued to a wholly owned subsidiary to
Upon full utilization of the warrants resolved upon by the EGM, as well as the outstanding warrants of series 2018/2021, the dilution effect amounts to approximately 4.53 percent of the total amount of outstanding shares and votes in the company. The dilution effect has been calculated as the number of additional shares and votes if the warrants are fully utilized in relation to the sum of the current number of shares and votes and the number of additional shares and votes at full utilization of the warrants.
Other resolutions
The EGM resolved to authorise the chief executive officer to make minor adjustments and clarifications of the resolutions adopted by the EGM.
For further information, please contact:
Peter Nordkild, CEO,
Phone: +45 25 47 16 46
E-mail: peter.nordkild@asarinapharma.com
Jakob Dynnes Hansen, CFO,
Phone: +45 5132 3698
E-mail: jakob.dynnes@asarinapharma.com
Certified advisor
Box 7405,
103 91 Stockholm
Phone: +46 8-463 83 00
E-mail: certifiedadviser@penser.se
About
https://news.cision.com/asarina-pharma/r/asarina-pharma-s-extraordinary-general-meeting,c3013880
https://mb.cision.com/Main/17069/3013880/1177517.pdf
(c) 2020 Cision. All rights reserved., source